Probenecid-induced changes in the clearance of pranoprofen enantiomers

Chirality

Volumn 15, Issue 4, 2003, Pages 318-323

  Imai, Teruko ^a   Nomura, Tadayuki ^a   Otagiri, Masaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Chiral inversion; Drug interaction; Enantioselective disposition; Glucuronidation; Plasma concentration

Indexed keywords

GLUCURONIDE; PRANOPROFEN; PROBENECID; SODIUM HYDROXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ENANTIOMER; ENANTIOSELECTIVITY; ISOMER; KIDNEY MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RACEMIC MIXTURE; TISSUE DISTRIBUTION; URINARY EXCRETION; URINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPYRANS; DRUG INTERACTIONS; GLUCURONIDES; MALE; METABOLIC CLEARANCE RATE; PROBENECID; PROPIONIC ACIDS; RABBITS; STEREOISOMERISM; TISSUE DISTRIBUTION; URICOSURIC AGENTS;

EID: 0037270597     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.10208     Document Type: Conference Paper

References (25)

1. Brown GR. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 1993;24:289-300.
2. Gimeno MJ, Martinez M, Granero L, Torres-Molina F, Peris JE. Influence of probenecid on the renal excretion mechanisms of cefadroxil. Drug Metab Dispos 1996;24:270-272.
3. Resetar A, Minick D, Spector T. Glucuronidation of 3′-azido-3′-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem Pharmacol 1991;42:559-568.
4. Guarino AM, Conway WD, Fales HM. Mass spectral identification of probenecid metabolites in rat bile. Eur J Pharmacol 1969;8:244-252.
5. Smith PC, Langendijk PN, Bosso JA, Benet LZ. Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. Clin Pharmacol Ther 1985;38:121-127.
6. Spahn H, Spahn I, Benet LZ. Probenecid-induced changes in the clearance of carprofen enantiomers: a preliminary study. Clin Pharmacol Ther 1989;45:500-505.
7. Upton RA, Williams RL, Buskin JN, Jones RM. Effects of probenecid on ketoprofen kinetics. Clin Pharmacol Ther 1982;31:705-712.
8. Hedaya MA, Elmquist WF, Sawchuk RJ. Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm Res 1990;7:411-417.
9. de Miranda P, Good SS, Yarchoan R, Thomas RV, Blum MR, Myers CE, Broder S. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 1989;46:494-500.
10. Kornhauser DM, Petty BG, Hendrix CW, Woods AS, Nerhood LJ, Bartlett JG, Lietman PS. Probenecid and zidovudine metabolism. Lancet 1989;2:473-475.
11. Abernethy DR, Greenblatt DJ, Ameer B, Shader RI. Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. J Pharmacol Exp Ther 1985;234:345-349.
12. Kamali F. The effect of probenecid on paracetamol metabolism and pharmacokinetics. Eur J Clin Pharmacol 1993;45:551-553.
13. Nomura T, Imai T, Otagiri M. Stereoselective disposition of pranoprofen, a nonsteroidal antiinflammatory drug, in rabbits. Biol Pharm Bull 1993;16:298-303.
14. Palylyk EL, Jamali F. Ketoprofen-probenecid interaction in the rat: a probenecid concentration-dependent stereoselective process. J Pharm Sci 1993;82:296-300.
15. Spahn H, Iwakawa S, Bevet LZ, Lin ET. Influence of probenecid on the urinary excretion rates of the diastereomeric benoxaprofen glucuronides. Eur J Drug Metab Pharmacokinet 1987;12:233-237.
16. Foster RT, Jamali F, Russell AS. Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: influence of probenecid. Eur J Clin Pharmacol 1989;37:589-594.
17. Bischer A, Iwaki M, Zia-Amirhosseini P, Benet LZ. Stereoselective reversible binding properties of the glucuronide conjugates of fenoprofen enantiomers to human serum albumin. Drug Metab Dispos 1995;23:900-903.
18. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, Endou H. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002;301:797-802.
19. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 2002;277:26934-26943.
20. Masuda S, Saito H, Inui KI. Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1. J Pharmacol Exp Ther 1997;283:1039-1042.
21. Cox PG, van Os CH, Russel FG. Accumulation of salicylic acid and indomethacin in isolated proximal tubular cells of the rat kidney. Pharmacol Res 1993;27:241-252.
22. Groves CE, Morales M, Wright SH. Peritubular transport of ochratoxin A in rabbit renal proximal tubules. J Pharmacol Exp Ther 1998; 284:943-948.
23. Watari N, Aizawa K, Kaneniwa N. Dose- and time-dependent kinetics of the renal excretion of nitrofurantoin in the rabbit. J Pharm Sci 1985; 74:165-170.
24. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 1981;6:135-151.
25. von Moltke LL, Manis M, Harmatz JS, Poorman R, Greenblatt DJ. Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid. Biopharm Drug Dispos 1993;14:6119-6130.